Extended Data Fig. 1: CONSORT diagram for the JUPITER-02 Phase III study. | Nature Medicine

Extended Data Fig. 1: CONSORT diagram for the JUPITER-02 Phase III study.

From: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Extended Data Fig. 1

Between Nov 10, 2018, and Oct 20, 2019, 408 NPC patients were screened for eligibility at 35 sites from mainland China, Taiwan and Singapore. A total of 289 eligible patients were randomized 1:1 to the toripalimab combination arm (n = 146) or the placebo combination arm (n = 143). After completion of chemotherapy, 231 patients continued to receive maintenance treatment (115 in the toripalimab arm and 118 in the placebo arm).

Back to article page